Clicky

Santen Pharmaceutical Co(SNPHY)

Description: Santen Pharmaceutical Co., Ltd. researches and develops, produces, and markets pharmaceuticals and medical devices in Japan and internationally. It offers prescription pharmaceutical products for glaucoma and ocular hypertension, dry eyes, allergic conjunctivitis, severe keratitis with dry eyes, vernal keratoconjunctivitis, uveitis, wet age-related macular degeneration, and myopia; and over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.


Keywords: Medicine Hypertension Macular Degeneration Glaucoma Wet Age Related Macular Degeneration Coma Uveitis Myopia Allergic Conjunctivitis Conjunctivitis Ocular Hypertension Counter Pharmaceutical Products Over The Counter Pharmaceutical Products Prescription Pharmaceutical Products Keratoconjunctivitis Markets Pharmaceuticals Pharmaceuticals And Medical Devices Vernal Santen Pharmaceutical Severe Keratitis Vernal Keratoconjunctivitis

Home Page: www.santen.com

Grand Front Osaka Tower A
Osaka, 530-8552
Japan
Phone: 81 6 7664 8621


Officers

Name Title
Mr. Takeshi Ito Pres, CEO & Representative Director
Mr. Kazuo Koshiji Chief Financial Officer & Chief Risk Officer
Mr. Minori Hara Chief Digital & Information Officer
Ms. Kaori Itagaki Gen. Mang. of Investor Relations Group
Ms. Mika Masunari Gen. Counsel & Chief Compliance Officer
Ms. Nobuko Kato Chief Communications Officer
Mr. Satoshi Suzuki Sr. Corp. Officer & Head of Corp. Devel. Division
Mr. Shinichi Teramachi Corp. Officer, Head of Sales Department & Japan Sales and Marketing Division
Mr. Ippei Kurihara Corp. Officer and Head of Marketing Department, Japan Bus., Japan Sales & Marketing Division
Mr. Kenji Morishima Corp. Officer & Head of China Product Devel. Department

Exchange: PINK

Country: US

Currency: US Dollar ($)

Forward PE: 12.9199
Trailing PE: 16.5745
Price-to-Book MRQ: 1.3902
Price-to-Sales TTM: 0.0114
IPO Date:
Fiscal Year End: March
Full Time Employees: 4315
Back to stocks